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The structurefunction relationship of the human integrin VLA-4 (a4/,fIl; CD49d/CD29), has been studied in the human B-cell line Ramos by 
immunochemical nd functional analysis. Ramos cells expressed the I50-kDa non-proteolyzed form of the a4 chain, which could be digested upon 
mild trypsin treatment to generate the 80- and 65kDa protcolyzed forms, as well as a4 polypeptides of 55 and 50 kDa. In addition, treatment of 
Ramos cells with high doses of pronase predominantly ielded the 55 and 50-kDa a4 peptides. The trypsin-generated 80- and 6%kDa a4 
polypcptides, but not the 55 and 50-kDa fragments. were able to associate with the /3l chain. Distinct anti-VLA4 mAb against four different a4 
epitopes, referred to as cpitopes A, B I, 82, and C, recognized the 150-kDa 4 chain both associated or non-associated with the PI chain. The a4 
proteolytic forms of 80, 65 and 50 kDa were precipitated by the anti-a4 mAb directed against he four different a4 epitopes. On the other hand, 
the 55-kDa a4 pcptide was present in precipitates from anti-a4 mAb specific for epitopes A, Bl and C, but absent in precipitates from the anti-a4 
mAb specific for epitopc 92. The diffcrcnt adhesive capacities of the VLA-4 integrin, namely the interaction with a 38-kDa fibronectin fragment 
containing the CS-I region of plasma fibronectin (Fn-38), the binding to the vascular cell adhesion molecule-l (VCAM-I), or the ability to mediate 
the anti-a4-induced cell aggregation, were not altered on VLA-4 from cells upon mild trypsin treatment, when compared to non-treated cells. 
However, the 55- and SO-kDa a4 forms generated by high-dose pronase cell treatment, failed to mediate cell interaction with Fn-38 or VCAM-I 
ligands, and cell aggregation could not be triggered through VLA-4 under these conditions. 
VLA antigen; Integrin; Leukocyte adhesion 
1. INTRODUCTION 
The VLA-4 integrin (a4iPl; CD49d/CD29) is a leu- 
kocyte glycoprotein involved in both cell-extracellular 
matrix and cellcell interactions [1,2]. VLA-4 is the leu- 
kocyte receptor for the CS-1 region of plasma fibro- 
nectin [3-51, as well as for the vascular cell adhesion 
molecule VCAM-1 [6,7], and also mediates cell aggrega- 
tion through an LFA-l/ICAM-1 independent mecha- 
nism [8,9]. The a4ipl VLA-4 heterodimer is composed 
of a chain of 150 kDa (a4 chain) non-covalently associ- 
ated to a subunit of 130 kDa @l) [lO,l 11. The 150-kDa 
~4 subunit can be proteolyzed ‘in viva’ or ‘in vitro’ to 
generate a4 polypeptides of 80 and 65 kDa [lo-121, 
although the physiologic significance of this proteolysis 
is unknown. We have defined four distinct epitopes on 
the VLA-a4 chain (A, Bl, B2, and C) by both immu- 
nological and functional criteria [13]. Anti-epitope A, 
Bl, and B2 mAb directly affected the adhesive cell inter- 
Abbreviations: VLA, very late activation antigen; mAb, monoclonal 
antibody(ies); Fn, libronectin; VCAM-I, vascular cell adhesion mole- 
cule-l; LFA-1, lymphocyte-function associated antigen-l; ICAM-I, 
intercellular adhesion molecule-l. 
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actions mediated by VLA4, whereas the anti-epitope C 
mAb did not [ 131. Here we have studied the correlation 
of the presence of a4 proteolytic peptides with the dis- 
tinct a4 epitopes and with the VLA4 sites of ligand 
interaction. 
2. MATERIALS AND METHODS 
2.1. Cells and protease treatment 
The human B-cell line Ramos, derived from a Burkitt tymphoma, 
was obtained from the American Type Culture Collection (Rockville, 
MD), and was grown in RPM1 1640 medium (Flow Laboratoires, 
Irvine, Scotland) supplemented with 10% fetal calf serum, 2 mM 
L-glutamine, and 50 ,@ml gentamicine. For trypsin treatment, radio- 
labeled cells were incubated (5 x lO?ml) in trypsin EDTA lx (Flow 
Laboratoires) for 3 min at 37°C. For Pronase treatment, radiolabeled 
cells were incubated in PBS (5 x 106/ml) with 20 &ml or 100 /*g/ml 
pronase (Sigma, St. Louis, MO) for 30 min at 37’C. After proteolysis, 
cells were washed and lysed, and tysates were subjected to immunopre- 
cipitation. 
2.2. Monoclonal antibodies, jibronectin ,fragments and soluble VCAM-1 
The anti-a4 HPl/7 (epitope A), HP2/1 (epitope Bl), HP2/4 (epitope 
B2), and B-5GI0 (epitope C) mAb, and the anti-#0 TS2/16 mAb, have 
been described previously [10,11,13,14]. The 38-kDa Fn fragment was 
prepared by tryptic digestion of human plasma Fn as described [15]. 
The recombinant soluble form of VCAM-1 was purified by immu- 
noaffinity chromatography from conditioned medium of CHO cells 
stably transfected with a truncated cDNA for VCAM-I (Lobb, R., et 
al., manuscript submitted). 
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2.3. Radiolabeling. immunoprecipitution and electrophoresis 
Cell suspensions were cell-surface radioiodinated in solution with 
chloroglycoluril (lodogen, Pierce Chemical Co., Rockford, IL). After 
protease treatments, cells were lyscd in PBS pH 7.4, 1% Triton X-100, 
1% hemoglobin, and I mM PMSF (a4//?I association conditions), or 
in PBSpH lO.5,2% Triton X-100, 1% hemoglobin, 0.3 M NaCI, 2 mM 
EDTA. and I mM PMSF (cr4//31 dissociation conditions). For immu- 
noprecipitation, the “‘I-labeled proteins were mixed with 100 ~1 of 
mAb-containing culture supernatants, followed by 100 ~1 of 187.1 
anti-mouse kappa chain and 30~1 of protein A from S. NUWW coupled 
to Sepharosc (Pharmacia Fine ChcmicaIs, Uppsala, Sweden). Immu- 
noprecipitates were processed as described [IO], and samples were 
subjected to SDS-( 10% acrylamidc) PAGE and autoradiography. 
For cell-attachment assays, Y6-well plates were coated with 100 ~1 
of 0.1 M NaHCO, containing IO @ml of 38-kDa Fn fragment or 5 
&ml of recombinant soluble VCAM-I, as described [13]. Then, cells 
(2 x l@/ml) were resuspended in RPM1 1% BSA and plated in dupli- 
cate on the coated plates (100 ~1 fnal volume). After 30 min of 
incubation at 37°C unbound cells were removed by washing, and 
bound cells were quantified by counting the cells from at least three 
different fields of known area. The number of cells on a non-washed 
well was referred as input cells (100% of binding). For antibody inhibi- 
tion ofcell attachment, cells were preincubated with 1: IO final dilution 
of mAb-containing culture supernatants before the adhesion assay. 
Homotypic aggregation assays were performed as described [Xl. Cells 
were incubated (2 x IOhlml) in duplicate in RPM1 5% fetal calf serum 
in the presence of I: 10 final dilution of mAb-containing culture super- 
natants (100 ~1 final volume), for 3 h at 37°C and 5% CO? into a cell 
incubator, and aggregation was dctcrmincd by visualization of the 
plate with an inverted microscope. Percent aggregation was measured 
by the following equation: percent aggregation = 100 x (I - (number 
of free cells)/(total number of cells)). 
3. RESULTS 
Four distinct epitopes (A, Bl, B2 and C) have been 
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defined previously on the VLA-a4 subunit, which show 
different immunological and functional properties [ 131. 
To analyze the topographic location on the a4 chain of 
these different antigenic sites, immunoprecipitation ex- 
periments on the B-lymphoblastoid ccl1 line Ramos 
were carried out by using mAb recognizing the four 
distinct a4 epitopes. Ramos cells were cell-surface ra- 
dioiodinated and lysed either under conditions which 
kept the a4/,!31 heterodimer associated (Fig. IA) or dis- 
sociated (Fig. lC, lanes 1 5), and then, the lysates were 
subjected to immunoprecipitation with the distinct anti- 
VLA-4 mAb. As observed, the mAb directed against the 
four different a4 epitopes recognized the 150-kDa 014 
subunit both associated to (A, lanes 1 4) or dissociated 
from (C, lanes l-4) the 13O-kDa /?l subunit, which was 
also recognized under both conditions by an anti-p1 
mAb (A and C, lanes 5). 
Next, radioiodinated cells were incubated under mild 
trypsin treatment conditions, lysed upon a4//Il associa- 
tion (Fig. lB, lanes 334) or dissociation (Fig. IC, lanes 
6-10) conditions, and precipitated with the anti-a4 or 
anti-p1 mAb. a4 polypeptides of 80, 65, 55 and 50 kDa 
were produced by the trypsin treatment and precipi- 
tated by an anti-a4 mAb (HP2/1, epitope Bl), in as- 
sociation with the /?l component (B, lane 3). When 
samples were precipitated with an anti-/?1 mAb, only 
the 80- and 65kDa a4 forms, but not the 55 and 50- 
kDa forms, were able to associate with the /?l subunit, 
which showed a proteolyzed form of 120 kDa under 
these conditions (B, lane 4). In Fig. lB, lanes 1 and 2, 
precipitates from control cells, using the anti-a4 HP2/1 
and anti;01 TS2/16 mAb, respectively, are shown. The 
four distinct anti-a4 mAb precipitated the 80-, 65-, and 
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Fig. I. Immunoprecipitation of a4 proteolytic polypeptides with distinct anti-a4 mAb upon a4iBl association or dissociation conditions. (A) 
Radioiodinated Ramos cells were lysed under cc4/pl association conditions, and lysates were precipitated with anti-a4 HP]/7 (lane I), HP2/l (lane 
2), HP214 (lane 3) and B-5G10 (lane 4) mAb, or with anti-PI TS2/16 (lane 5) mAb. (B) Radioiodinated cells were maintained non-treated (lanes 
I ,2) or were treated with trypsin (lanes 3,4). Cells were lysed under a4//?1 association conditions, and precipitated with anti-a4 HP211 (lanes I and 
3) and anti-/?1 TS2/16 (lanes 2 and 4) mAb. (C) Radioiodinated cells were maintained non-treated (lanes l-5) or were incubated with trypsin (lanes 
6-IO), 20 &ml pronase (lanes I I -IS), or 100 ,@ml pronase (lanes 1620) as described in section 2. Cells were lysed upon a4@l dissociation 
conditions, and lysates were preincubated with anti-a4 HP1/7 (lanes l,6, I I and l6), HP211 (lanes 2,7,12 and 17). HP214 (lanes 3,8,13 and 18), and 
B-5G10 (lanes 4,9,14 and 19) mAb, or with ant+1 TS2/16 (lanes 5,10,15 and 20) mAb. Immune complexes were isolated, and reduced samples 
were subjected to SDS-(10% acrylamide) PAGE and autoradiography. 
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Table I 
Functional properties of a4 proteolytic polypeptides 
Cell treatment” a4 polypeptidcs (kDa) 
----- ~~~~____ 
Fn-38 
Ceil binding tab Induction of cellb 
aggregation by 
Fn-38 VCAM-1 VCAM-I 




Pronase (20 ,@ml) 
Pronase (100 pg/ml) 
150 9026 2+1 92f6 2+1 41+17 52216 
80,65,55,50 82+16 3?2 83210 4+2 51+15 66+13 
(80,65),55.50 IO? 4 6f2 4_+1 6+3 
55,50 2il 2&l 2+1 2+1 _ 
“Ramos cells were treated with proteases as described in section 2. 
hCell attachment to Fn-38 of VCAM-I coated-plates was analyzed by ‘in vitro’ cell adhesion assays, in the presence or absence of anti-a4 HP2/] 
(epitope BI) mAb, as described in section 2. Results are expressed as mean *SE of percentage of binding, calculated from three separated 
experiments. 
‘Induction of homotypic cell aggregation with anti-a4 (epitopc A) or HP214 (cpitope 82) mAb was analyzed by ‘in vitro’ aggregation assays, as 
described in section 2. Kcsults are expressed as mean +SE of pcrccntage of ccl: iggregation, calculated from three separated experiments. 
50-kDa ~14 peptides (C, lanes 6-9). However, the 5% 
kDa form was precipitated by the anti-epitope A, anti- 
epitope Bl, and anti-epitope C mAb (C, lanes 6, 7 and 
9), but not by the anti-epitope B2 mAb (C, lane 8). 
Proteolytic treatment of radioiodinated Ramos cells 
was also performed by cell incubation with pronase 
(Fig. lC, lanes 1 l-20). Under low-dose pronase treat- 
ment, the relative amount of both the 80- and 65-kDa 
forms, with respect to the 55- and 50-kDa forms, 
decreased considerably, when compared to the trypsin- 
treated cells (C, lanes 1 l-14 vs. lanes 6-9). When a high 
dose of pronase was employed, the 55- and 50-kDa 
peptides were predominantly generated, and both of 
them precipitated by the anti-epitope A, anti-epitope 
Bl, and anti-epitope C mAb (C, lanes 16, 17 and 19), 
whereas the anti-epitope B2 mAb only precipitated the 
SO-kDa form (C, lane IS), similarly to that observed 
upon the trypsin incubation conditions. 
To study the structure-function relationship on the 
VLA-4 integrin, the cell adhesion processes mediated by 
VLA4 were investigated on both trypsin- and pronase- 
treated Ramos cells by ‘in vitro’ functional assays 
(Table I). The VLA-4 interaction either with a 3%kDa 
plasma fibronectin fragment containing the CS- 1 region 
(Fn-38), or with a recombinant soluble form of VCAM- 
1, as well as the capability to aggregate upon incubation 
with aggregation inducer anti-a4 mAb, were unaffected 
on cells treated with trypsin under mild conditions, as 
compared with untreated cells. As shown, the cell inter- 
action with Fn-38 or VCAM-I was completely blocked 
in the presence of the anti-a4 HI?/1 (epitope Bl) mAb, 
both in control or trypsin-treated cells. By contrast, cell 
treatment with pronase resulted in the abrogation of the 
three VLA-4-mediated adhesion activities (Table I), in- 
dicating that, upon the conditions in which the 55- and 
50-kDa a4 forms are mainly present, VLA-4 has no 
functional activity. 
4. DISCUSSION 
In this study, we have found a pattern of proteolytic 
degradation of the a4 protein composed of polypeptides 
of 80-, 65-, 55- and 50-kDa, which showed different 
functional properties and reacted differentially with 
anti-a4 mAb defining the distinct a4 epitopes (Table II). 
The results reported here demonstrate the existence of 
biochemical differences in the a4 epitopes previously 
defined on the basis of immunological and functional 
criteria [13]. In this respect, it is remarkable that we 
found that anti-epitope Bl and anti-epitope B2 mAb, 
known to cross-compete with each other [13], show dif- 
ferent functional properties in terms of induction of cell 
aggregation and that they precipitate distinct a4 
proteolytic fragments. By contrast, the anti-epitope A, 
anti-epitope Bl, and anti-epitope C mAb, which have 
distinct immunological and functional properties [ 131, 
precipitated the same a4 proteolytic pattern (Table II). 
The proteolytic ‘in vivo’ degradation of the VLA-a4 
subunit has been described, and appears to be regulated 
in a cell-type specific manner [2,10,1 I]. However, the 
functional meaning of this cleavage remains undis- 
covered. Our results indicate that the 80- and 65-kDa 
a4 forms, proteolyzed ‘in vitro’ on Ramos cells, have 
functional and immunological properties identical to 
the native l50-kDa protein. The exact location of the 
distinct a4 epitopes on the different a4 proteolytic poly- 
peptides is hampered by the fact that the 80- and 65- 
kDa polypeptides remain non-covalently associated 
after proteolysis [1 1,121. Interestingly, the 80- and 65- 
kDa 614 polypeptides, but not the 55- and 50-kDa forms, 
were able to associate ‘in vitro’ with the /31 chain and 
mediate all the cell adhesion functions due to the VLA4 
integrin. From our results, we hypothesize that the 80- 
and 65-kDa cr4 peptides can be further proteolyzed to 
generate the 55- and 50-kDa peptides, which cannot be 
123 
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Table II 
Immunological, biochemical and functional propcrtics of a4 intact and protcolyric pcptidcs 
~~ _~~~ -I____ 
a4 polypeptides Precipitation by anti-a4 mAb Associatiori with Fl1I1ctlofl” 
(kW 
____--.- PI chain 
A Bl B2 c; Fn-38 VCAM-I Aggregation 
150 + + + + + + t + 
80,65 + + t + t $ i 1~ 
55 + + + 
50 -t + + + 
” a4 epitopes A, Bl, B2 and C arc as described in ref. [13]. 
” VLA-4 interaction with Fn-38 or VCAM-I, or induction of ccl] aggregation by the anti-a4 HPII7 (cpitope A) or HP214 (cpitope 82) mAb. 
associated to the /31 chain. Thus, this additional pro- 
teolysis of the 80- and 65-kDa a4 fragments would 
produce the loss of VLA-4 cell-adhesion functions, and 
also the abrogation of epitope B2 on the 55-kDa frag- 
ment. 
Similarly to other integrins, the cell adhesion func- 
tions mediated by VLA-4 are dependent of the presence 
of divalent cations [l]. Some anti-p2 or anti-p3 integrins 
mAb, related to the integrin function, recognize divalent 
cation-dependent epitopes [16-l 81. However, all a4 
epitopes recognized by the distinct anti-&4 mAb here 
studied, including those which trigger cell aggregation 
and/or inhibited VLA-4 interaction with Fn or VCAM- 
I, were not dependent on the presence of divalent ca- 
tions (Fig. 1C; and data not shown). Furthermore, the 
anti-a4 mAb recognized the a4 chain independently of 
its association with the j31 chain. The VLA-4 integrin is 
exclusively expressed on leukocytes, and constitutes the 
molecule through which these cells interact with the 
splicing-regulated IIICS region of Fn, and also with 
activated endothelium via VCAM-1 [3-5,7]. In addi- 
tion, the existence of other unknown VLA-4 cellular 
ligands has been proposed [2,13]. The Fn amino-acid 
sequences which interact with VLA4 have been 
identified [4,19]. Thus, the finding and characterization 
of the distinct ligand binding sites on VLA-4 at a molec- 
ular level will be of crucial importance in order to design 
reagents which can interfere selectively with different 
VLA4 mediated adhesion functions. These can be 
potential therapeutic tools for the use in pathological 
processes involving leukocyte recognition of extracel- 
lular matrix proteins and migration towards inflamed 
tissues. 
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